Findings

What do systematic reviews say?

240 questions · 244 findings · 23 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 39 · 16%GRADE not reported 15 · 6.1%Very low 78 · 32%Low 52 · 21.3%Moderate 49 · 20.1%High 11 · 4.5%

Atypical antipsychotics vs placebo

Specific behaviour ‐ agitation

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Intervention not reported

Atypical antipsychotics vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 476 participants
Moderate

Intervention not reported

Atypical antipsychotic vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 577 participants
High

Intervention not reported

Atypical antipsychotic vs placebo · critically ill adults with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 500 participants
Moderate

Intervention not reported

Atypical AP vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 511 participants
Moderate

Intervention not reported

Atypical antipsychotic vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 577 participants
GRADE not reported

Intervention not reported

Typical antipsychoticvs atypical antipsychotic · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 447 participants
GRADE not reported

Intervention not reported

Atypical antipsychotic vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 440 participants
Moderate

Macrolide+tetracycline vs macrolides

Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral appliance or functional orthopaedic appliance vs placebo or no treatment

Signs and symptoms of atypical swallowing and speech production disturbances · Children with obstructive sleep apnoea (aged 15 years or younger)

The review found no eligible studies for this question.

1 finding from 1 review

Oral appliances and functional orthopaedic appliances for obstructive sleep apnoea in children 2016 · Cochrane All outcomes
The included study did not assess this outcome.
0 studies
No studies found

Frankel's function regulator-4 (FR-4) with lip-seal training vs no treatment

Signs and symptoms of atypical swallowing and speech production disturbances · Children and adolescents (over 80% aged 16 years or younger at treatment start) with anterior open bite (lack of vertical overlap or…

The review found no eligible studies for this question.

1 finding from 1 review

Orthodontic and orthopaedic treatment for anterior open bite in children 2014 · Cochrane All outcomes
Outcome proposed in the review but not found in any included study. The review states: 'The other outcomes proposed in this review were not found: stability of anterior open bite correction; reduction of snoring; signs…
0 studies
No studies found

LNG‐IUS vs medroxyprogesterone (MPA) 10 mg

Regression rate at 6 months · women with atypical endometrial hyperplasia

It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).

1 finding from 1 review

Oral and intrauterine progestogens for atypical endometrial hyperplasia 2018 · Cochrane Headline outcomes only
OR 2.76 [0.26, 29.73]
1 study · 19 participants
Very low

LNG‐IUS vs medroxyprogesterone (MPA) 10 mg

Nausea · women with atypical endometrial hyperplasia

It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).

1 finding from 1 review

Oral and intrauterine progestogens for atypical endometrial hyperplasia 2018 · Cochrane Headline outcomes only
OR 0.58 [0.28, 1.18]
1 study · 153 participants
Very low

LNG‐IUS vs medroxyprogesterone (MPA) 10 mg

Vaginal bleeding over 6‐month · women with atypical endometrial hyperplasia

Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).

1 finding from 1 review

Oral and intrauterine progestogens for atypical endometrial hyperplasia 2018 · Cochrane Headline outcomes only
OR 2.89 [1.11, 7.52]
1 study · 153 participants
Low

Typical vs atypical antipsychotics

All‐cause mortality · delirious patients

Typical showed no clear difference in mortality compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 1.71 [0.82, 3.53]
4 studies · 342 participants
Moderate

Typical vs atypical antipsychotics

Length of hospital stay · delirious patients

The review found no eligible studies for this question.

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Typical vs atypical antipsychotics

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · delirious patients

It is very uncertain whether typical changes adverse Effects ‐ EPS compared with atypical antipsychotics (very low certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 12.16 [0.55, 269.52]
2 studies · 198 participants
Very low

Typical vs atypical antipsychotics

Duration of delirium Days · delirious patients

The review found no eligible studies for this question.

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Typical vs atypical antipsychotics

Delirium resolution DRS, DRS‐R981 · delirious patients

Typical showed no clear difference in delirium resolution DRS, DRS‐R981 compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 1.1 [0.79, 1.52]
5 studies · 349 participants
Moderate